Panbela Therapeutics, Inc. (PBLA) |
|
1.31 0.03 (2.34%)
|
09-29 15:59 |
|
Open: |
1.28 |
Pre. Close: |
1.28 |
|
High:
|
1.35 |
Low:
|
1.22 |
|
Volume:
|
14,615 |
Market Cap:
|
4(M) |
|
|
|
Technical analysis |
as of: 2023-09-29 4:29:35 PM |
|
Short-term rate:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 1.65 One year: 1.79 |
| Support: |
Support1: 1.21 Support2: 1 |
| Resistance: |
Resistance1: 1.41 Resistance2: 1.53 |
| Pivot: |
1.31  |
| Moving Average: |
MA(5): 1.28 MA(20): 1.34
MA(100): 3.76 MA(250): 57.89 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 36.1 %D(3): 30.2 |
| RSI: |
RSI(14): 38.7 |
| 52-week: |
High: 384 Low: 1.21 |
| Average Vol(K): |
3-Month: 928 (K) 10-Days: 22 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PBLA ] has closed above bottom band by 47.2%. Bollinger Bands are 94.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for {EMPTY} bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.35 - 1.36 |
1.36 - 1.36 |
|
Low:
|
1.21 - 1.21 |
1.21 - 1.22 |
|
Close:
|
1.3 - 1.31 |
1.31 - 1.32 |
|
Company Description |
|
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota. |
Headline News |
Tue, 26 Sep 2023
Panbela Announces Issuance of New Patent in China for Claims of ... - BioSpace
Tue, 19 Sep 2023
Panbela to Present at the LD Micro Investor Conference - GlobeNewswire
Tue, 05 Sep 2023
Panbela Announces Issuance of New Patent in Chile for Claims of a ... - GlobeNewswire
Mon, 28 Aug 2023
Panbela to Present at H.C. Wainwright 25th Annual Global - GlobeNewswire
Sun, 13 Aug 2023
Panbela Therapeutics, Inc. (NASDAQ:PBLA) Q2 2023 Earnings Call Transcript - Yahoo Finance
Wed, 19 Jul 2023
Panbela Therapeutics to Receive a Total Up to $9.5 Million for ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
3 (M) |
| Shares Float |
3 (M) |
|
% Held by Insiders
|
0.8 (%) |
|
% Held by Institutions
|
4.4 (%) |
|
Shares Short
|
84 (K) |
|
Shares Short P.Month
|
49 (K) |
Stock Financials |
|
EPS
|
179.61 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.84 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-93.6 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-22 (M) |
|
Levered Free Cash Flow
|
-9 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.71 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.18 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
